Horizons S&P Financial Select Sector Covered Call ETF HFIN 深 沪
已收盘 10-08 16:00:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Einride and Lorenz Bring Autonomous Fleet to Production Facility in Germany
Einride and Lorenz have deployed four autonomous, electric vehicles at Lorenz's Neunburg vorm Wald plant, replacing diesel transport to reduce CO₂ emissions. The vehicles, managed by Einride's Saga AI platform, handle internal transport of goods and pallets, with two electric trucks as backup. Lorenz won third place at the 2026 German Logistics Awards for their innovative "PATHFINDER" concept. The five-year project aims to integrate autonomous an...
11-05 08:00
Hamilton Global Financials ETF announces May 2026 monthly cash distributions
Hamilton Global Financials ETF (HFG:CA) declares CAD 0.07/share monthly dividend. Hamilton Canadian Bank Mean Reversion Index ETF (HCA:CA) declares CAD 0.096/share monthly dividend. Hamilton Canadian ...
05-22 21:19
GRAIL signals 22%-32% 2026 Galleri sales growth while starting Epic Aura integrations
Earnings Call Insights: GRAIL, Inc. (GRAL) Q1 2026 Management View "This quarter, we saw continued strong commercial momentum with expanding physician adoption, increasing engagement across health sys...
05-06 10:32
GRAIL To Reveal New Data From NHS-Galleri And PATHFINDER 2 At 2026 ASCO Annual Meeting
GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further
04-22 04:55
Hims latest offering, Grail's Galleri cancer test, fails U.K. study
GRAIL (GRAL) shares crashed on Thursday in reaction to a failure in a large U.K.-based clinical study for its Galleri multi-cancer screening test, which was added to the Hims & Hers (HIMS) telehealth ...
02-21 02:25
Why Grail Stock Is Sinking Friday
GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.
02-20 18:18
GRAIL Announces Topline Results For NHS-Galleri Trial; Primary Endpoint Of Statistically Significant Combined Stage III-IV Reduction Was Not Met
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over TimeGRAIL Announces U.S. Sales Force Expansion Based on Strong NHS-Galleri and
02-20 05:12
